Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data TRINITY BIOTECH PLC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
100
99.6
99.1
97
90.4
102
81.1
62.5
56.8
61.6
Cost of revenue
53.7
56.1
57.3
55.6
52.3
53.4
47.7
45.3
37.4
40.1
Gross profit
46.5
43.5
41.9
41.4
38.1
48.6
33.5
17.3
19.5
21.4
Research and development
5.07
5.04
5.66
5.37
5.33
5.08
4.5
4.14
4.38
4.54
Selling, general and administrative
28.2
30.4
32.2
29.5
27.7
26.4
22.5
27
31.2
28.8
Operating income
13.5
-39.8
-37.7
-20.2
-24.1
0.08
3.94
-19.3
-27
-21.2
Interest expense
4.05
5.44
5.41
5.08
6.58
6.75
7.09
24.7
11.1
9.57
Interest income
13.5
3.15
3.2
2.12
0.7
0.04
1.22
0.3
1.17
0
Pre-tax income
22.9
-42.1
-39.9
-23.2
-30
-6.63
-1.92
-43.8
-36.9
-30.7
Income tax
0.76
-3.56
-1.21
-0.53
-1.01
-0.62
-0.07
-0.19
-0.06
0.49
Income from continuing operations
22.2
-38.6
-38.7
-22.7
-29
-6.01
-1.85
-43.6
-36.9
-31.2
Net income
21.8
-101
-40.3
-22.1
-28.9
-6.39
0.88
-41
-24
-31.8
EBITDA
13.6
-39.4
-37.1
-20.1
-24.1
0.12
41.9
-19.3
-27
-21
Balance sheet
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
102
77.1
57.6
30.3
15.2
27.3
25.9
6.58
3.69
5.17
Receivables
22.6
20.7
24.4
21
22.7
16.1
15.8
13.9
16.1
Inventory
32.6
32.8
30.4
32
30.2
29.1
22.5
19.9
19.4
Total current assets
133
113
86.7
71.4
83.3
72.7
46.7
39
41.1
Property, plant and equipment
13.4
5.8
5.36
9.29
8.55
5.92
5.68
1.89
4.62
Lease right-of-use assets
10.1
5.23
Total assets
250
193
152
131
130
119
92.1
59.4
103
Accounts payable
9.02
8.05
8.12
7.83
7.1
6.76
6.21
3.89
6.83
Total current liabilities
25.3
21.2
17.6
19.4
27.1
100
17.3
15
32.1
Total liabilities
141
128
108
126
133
119
94.3
83.4
138
Total debt
0
1.04
1.04
99.9
1.04
1.04
Paid-in capital
16.2
16.2
16.2
16.2
16.2
16.2
46.5
46.6
63.4
Retained earnings
110
75.8
55.3
16.1
10.6
12.6
-26.7
-48.6
-79.1
Total equity
214
109
65.2
44.1
4.71
-2.22
-0.32
-2.18
-23.9
-35.2
Total liabilities and equity
250
193
152
131
130
119
92.1
59.4
103
Cash flow statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
22.2
-38.6
-38.7
-22.7
-29
-6.01
-1.85
-43.6
-36.9
-31.2
Depreciation and amortization
0.07
0.41
0.53
0.08
0
0.04
38
0
0
0.2
Cash from operations
13.2
10.2
9.25
7.23
5.42
23.8
13.2
-0.92
-11.6
-4.19
Capital expenditures
-7.09
-4.22
-4.84
-7.53
-2.12
-3.18
-1.81
-1.1
-0.8
-0.41
Cash from investing
-27.7
-21.9
-16.2
-17.4
-11.9
-10.2
-8.69
-5.98
24.8
-23
Debt issued
0
4.52
1.76
0
0
Stock issued
2.94
0.86
0
0
25.3
0
7.39
Share buybacks
-9.32
-7.8
-0.43
Dividends paid
5.1
Cash from financing
108
-13.4
-12.6
-16.9
-7.53
-2.72
-6.02
-12.3
-16
28.8
Exchange rate effect
-0.13
0.16
0.07
-0.3
0.09
0.09
0.06
-0.11
-0.04
-0.18
Net change in cash
93
-25
-19.6
-27
-14
10.8
-1.47
-19.2
-2.84
1.65
Free cash flow
6.06
6.01
4.41
-0.3
3.3
20.6
11.4
-2.02
-12.4
-4.6
Interest paid
0.03
0.06
0.05
0.04
1
0.05
0.01
0
0
Income taxes paid
-0.46
-1.17
-0.84
0.42
0.02
0.97
-1.62
0.02
-0.31
-1.01
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. Valuation uses the share price of $6.76 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
34.8%
Gross profit / revenue.
Operating margin
-34.4%
Operating income / revenue.
EBITDA margin
-34.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-49.9%
Pre-tax income / revenue.
Net margin
-51.6%
Net income / revenue.
FCF margin
-7.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-6.8%
Cash from operations / revenue.
Return on assets (ROA)
-39.1%
Net income / average total assets.
R&D / revenue
7.4%
Research and development expense / revenue.
SG&A / revenue
46.8%
Selling, general and administrative expense / revenue.
Capex / revenue
0.7%
Capital expenditures / revenue.
D&A / revenue
0.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
8.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-8.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-7.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
10.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-13.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-10.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
73.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-4.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-4.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.28x
Current assets / current liabilities.
Quick ratio
0.66x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.16x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
134.1%
Total liabilities / total assets.
Interest coverage
-2.21x
Operating income / interest expense.
Working capital
$9.0M
Current assets - current liabilities.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.76x
Revenue / average total assets.
Fixed asset turnover
18.9x
Revenue / average property, plant and equipment.
Inventory turnover
2.04x
Cost of revenue / average inventory.
Days inventory
179 days
365 x average inventory / cost of revenue.
Receivables turnover
4.11x
Revenue / average receivables.
Days sales outstanding
89 days
365 x average receivables / revenue.
Days payables
49 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
219 days
Days inventory + days sales outstanding - days payables.
Valuation
Metric
Value
How it is calculated
Market cap
$5.5M
Share price x shares outstanding.
Enterprise value
$329.8K
Market cap + total debt - cash - short-term investments.
P/S
0.09x
Market cap / revenue.
EV/Sales
0.01x
Enterprise value / revenue.
FCF yield
-83.6%
Free cash flow / market cap.
Earnings yield
-578.3%
Net income / market cap (the inverse of P/E).
What was TRINITY BIOTECH PLC's revenue in fiscal 2024?
TRINITY BIOTECH PLC reported revenue of $61.6M for fiscal 2024, 8.3% higher than the year before.
Was TRINITY BIOTECH PLC profitable in fiscal 2024?
No. It reported a net loss of $31.8M.
How much free cash flow did TRINITY BIOTECH PLC generate in fiscal 2024?
Cash from operations of $4.2M minus capital expenditures of $405.0K left free cash flow of -$4.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.